A significant breakthrough was achieved with the discovery of N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA), a highly potent and specific GLUT5 inhibitor, shown to significantly reduce fructose-driven proliferation in BC cell lines (Thompson et al. 2016) (Fig. 3). Here, SLC2A5 is linked to breast cancer.